Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 469

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 469
---
    |
| Unwinding of discounting of provisions(d)       |    -44 |    -51 |    |  -17 |    |
| Net interest cost related to employee benefits  |    -64 |    -70 |    |  -46 |    |
| Gains/(losses) on disposals of financial assets |      — |     -1 |    |    1 |    |
| Net interest expense on lease liabilities       |    -42 |    -37 |    |  -40 |    |
| Other(e)                                        |   -224 |   -523 |    |    3 |    |
| Net financial income/(expenses)                 |   -554 |   -709 |    | -225 |    |
| comprising: Financial expenses                  | -1,073 | -1,293 |    | -430 |    |
| Financial income                                |    519 |    584 |    |  205 |    |

(a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued

operation.

(b) Includes net gains/(losses) on interest rate and currency derivatives used to manage debt: €( 45) million in 2024 , €( 67) million in 2023 , €( 11) million in

2022 .

(c) Includes net gains on interest rate and currency derivatives used to manage cash and cash equivalents: €( 25) million in 2024 , €( 13) million in 2023 ,

€ 68million in 2022 .

(d) Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note D.19.).

(e) Includes a financial expense of € 291 million for the remeasurement of the liability recognized in the balance sheet for estimated future royalties on

Beyfortus sales in the US. In 2023 , that expense amounted to € 541 million, reflecting the successful launch of Beyfortus (see Note C.2.).

T he impact of the ineffective portion of hedging relationships was immaterial in 2024 , 2023 and 2022 .

D.30. Income tax expense

Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the

United States.

The table below shows the allocation of income tax expense between current and deferred